[Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia].
OBJECTIVE
To explore the relation of the serum level of sIL-2R in relapse patients with acute lymphoblastic leukemia (ALL).


METHODS
With ELISA, we determined the levels of sIL-2R of 48 patients with ALL after their first diagnoses, complete remission 1 and relapse. The levels of sIL-2R of 30 patients from complete remission 1 to relapse were monitored.


RESULTS
The levels of sIL-2R were higher in the relapse group and first diagnosed group than in the control. The levels of sIL-2R were higher in the relapse group and first diagnosed group than in the complete remission 1 group. However, the difference between the complete remission 1 and the control had no statistical significance. When we determined the levels of sIL-2R dynamically, we found that after complete remission, the levels of sIL-2R decreased, however, before one month of hematological relapse, the levels of sIL-2R increased.


CONCLUSIONS
Monitor of the level of sIL-2R can predict impending relapse of patients with ALL and is helpful to early diagnosis of relapse.
Liu
Jin
J
Department of Hematology, Peking University Shenzhen Hospital, Shenzhen 518036, China. liubs6666@tom.com
Wu
Deng-shu
DS
Zhang
Shen
S
Yan
Chen-hua
CH
Zhou
Yu
Y
Zhang
Yong-ding
YD
Qi
Zhen-hua
ZH
D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism* / Q000473:pathology; D015375:Receptors, Interleukin-2 / Q000097:blood*
D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2